Catalog No.: PC-28067Not For Human Use, Lab Use Only.
TRI-611 is a potent, selective, CNS-penetrant molecular glue degrader of ALK, promotes the ubiquitination and degradation of ALK fusion alleles with clinically relevant acquired TKI resistance mutations.
TRI-611 is a potent, selective, CNS-penetrant molecular glue degrader of ALK, promotes the ubiquitination and degradation of ALK fusion alleles with clinically relevant acquired TKI resistance mutations.
TRI-611 promotes tumor regression with daily oral dosing in both subcutaneous and intracranial models of ALK+ NSCLC.
TRI-611 shows broad selectivity across the global proteome including closely related kinases such as NTRK1, allowing for sustained high target coverage, including in the CNS, without the off-target liabilities that are associated with TKIs.
TRI-611 brings ALK and cereblon together through a unique binding mechanism that works independently of the kinase active site and harnesses the body’s innate protein-degradation machinery to selectively eliminate the ALK fusion protein.
